HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

N-acetylcarnosine

RN given refers to (L)-isomer; structure given in first source
Also Known As:
CL 1700; N-acetyl-L-carnosine aluminum; N-acetylcarnosine, (DL)-isomer
Networked: 37 relevant articles (9 outcomes, 11 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Babizhayev, Mark A: 27 articles (12/2016 - 01/2002)
2. Yegorov, Yegor E: 7 articles (01/2016 - 01/2010)
3. Kasus-Jacobi, Anne: 4 articles (10/2012 - 01/2009)
4. Babizhayev, M A: 3 articles (10/2011 - 06/2001)
5. Yegorov, Y E: 2 articles (10/2011 - 02/2011)
6. Guiotto, Andrea: 2 articles (11/2009 - 01/2009)
7. Micans, Philip: 2 articles (11/2009 - 01/2009)
8. Deyev, Anatoly I: 2 articles (01/2004 - 01/2002)
9. Yermakova, Valentina N: 2 articles (01/2004 - 01/2002)
10. Hu, Hao: 1 article (10/2018)

Related Diseases

1. Cataract (Cataracts)
2. Macular Degeneration (Age-Related Maculopathy)
01/01/2009 - "The common blinding affections presenting in developed countries such as, senile macular degeneration, hereditary chorioretinal dystrophies, diabetic retinopathy are poorly represented in our current summary of vital-statistics and will be reported inherent in next N-acetylcarnosine ophthalmic drug studies. "
01/01/2010 - "Although these therapies remain on hold pending further investigation, we present growing evidence demonstrating the ability of N-acetylcarnosine (lubricant eye drops) or carcinine pharmacological chaperone therapy to act as novel treatments for age-related cataracts, age-related macular degeneration, and ocular complications of diabetes. "
11/01/2009 - "Overall, accumulated study data demonstrate that the IVP-designed new vision-saving drugs, including N-acetylcarnosine eyedrops, promote health vision and prevent vision disability from senile cataracts, primary open-angle glaucoma, age-related macular degeneration, diabetic retinopathy, and aging. "
06/01/2012 - "N-acetylcarnosine 1% lubricant eye drops are considered as an auto-induction prodrug and natural ocular redox state balance therapies with implications in prevention and treatment of serious eye diseases that involve pathways of continuous oxidative damage to ocular tissues(cataracts, primary open-angle glaucoma, age-related macular degeneration) and sight-threatening glycosylation processes (diabetic retinopathy and consequent visual impairment) important for public health. "
08/01/2012 - "A growing evidence and discussion of recent patents are presented in this study that demonstrate the ability of N-acetylcarnosine (lubricant eye drops) or carcinine (lubricant eye drops) (universal antioxidant and deglycation agent) resistant to enzymatic hydrolysis with carnosinase to act as pharmacological chaperones, to decrease oxidative stress and ameliorate oxidative and excessive glycation stress-related eye disease phenotypes, suggesting that the field of chaperone therapy might hold novel treatments for age-related cataracts, age-related macular degeneration (AMD) and ocular complications of diabetes (OCD). "
3. Vision Disorders (Hemeralopia)
11/01/2009 - "N-acetylcarnosine, as an innovative medical science tool and component of the home medicine and alternative medicine approaches, has the potential to alleviate visual impairment and its associated social, economic, and political woes for an aging population."
01/01/2009 - "The results of this study provide a substantial basis for further evaluation of N-acetylcarnosine eye drops patented by IVP in the treatment and prevention of visual impairment in the temporal cross-sections of an older population several years apart. "
11/01/2009 - "In a cohort in excess of 50,500 various patients seeking cutting-edge medical care, the N-acetylcarnosine topical eyedrops target therapy was demonstrated to have significant efficacy, safety, and good tolerability for the prevention and treatment of visual impairment in this older population with relatively stable patterns of causes for blindness and visual impairment. "
01/01/2009 - "The ophthalmic drug N-acetylcarnosine eye drop formulation with sustained time- release and increased absorption of L-carnosine in the aqueous humor (a prolonged effective dose) showed follow-up treatment efficacy for age-related cataracts for enrolled patients into the randomized double blind placebo controlled crossover clinical trial, and in over 50250 various cohort patients, was demonstrated to have an efficacy, safety and good tolerability for prevention and treatment of visual impairment in the older population data base. "
11/01/2009 - "Overall, accumulated study data demonstrate that the IVP-designed new vision-saving drugs, including N-acetylcarnosine eyedrops, promote health vision and prevent vision disability from senile cataracts, primary open-angle glaucoma, age-related macular degeneration, diabetic retinopathy, and aging. "
4. Diabetic Retinopathy (Retinopathy, Diabetic)
01/01/2009 - "The common blinding affections presenting in developed countries such as, senile macular degeneration, hereditary chorioretinal dystrophies, diabetic retinopathy are poorly represented in our current summary of vital-statistics and will be reported inherent in next N-acetylcarnosine ophthalmic drug studies. "
11/01/2009 - "Overall, accumulated study data demonstrate that the IVP-designed new vision-saving drugs, including N-acetylcarnosine eyedrops, promote health vision and prevent vision disability from senile cataracts, primary open-angle glaucoma, age-related macular degeneration, diabetic retinopathy, and aging. "
06/01/2012 - "N-acetylcarnosine 1% lubricant eye drops are considered as an auto-induction prodrug and natural ocular redox state balance therapies with implications in prevention and treatment of serious eye diseases that involve pathways of continuous oxidative damage to ocular tissues(cataracts, primary open-angle glaucoma, age-related macular degeneration) and sight-threatening glycosylation processes (diabetic retinopathy and consequent visual impairment) important for public health. "
01/01/2009 - "In the patented ophthalmic formulations, the designed leucyl-histidylhydrazide (not hydrolizable by carnosinase substrate) is endowed with a highly evolved structure optimized for the bioactivation of a N-acetylcarnosine dipeptide prodrug, targeting therapeutics of the main DOC: cataract, diabetic retinopathy, central retinal vein occlusion, central retinal artery occlusion and neovascular glaucoma. "
5. Eye Diseases (Eye Disease)
10/01/2012 - "The discovery of naturally occurring carnosine derivatives introduces N-acetylcarnosine and carcinine as effective medical treatment for sight-threatening eye disorders."
01/01/2009 - "Potentiation of intraocular absorption and drug metabolism of N-acetylcarnosine lubricant eye drops: drug interaction with sight threatening lipid peroxides in the treatment for age-related eye diseases."
12/01/2016 - " •This work considers mitochondrial reactive oxygen species (ROS) effects in the aging eye•The excessive oxidative damage is a major factor of the eye diseases (cataract, primary open-angle glaucoma)•The conventional antioxidants are not selectively taken up by mitochondria of the cells•The author developed the new ophthalmic compositions of mitochondria-targeted antioxidants•The formulation comprises N-acetylcarnosine combined with mitochondria-targeted rechargeable antioxidant•Mitochondrial targeting of antioxidants represents a promising therapeutic approach•A number of ROS-related ocular diseases of the aging eye can be treated."
01/01/2014 - "The preliminary longitudinal studies of elderly individuals suggest that longer telomeres are associated with better survival and an advanced oral nutritional support with non-hydrolyzed carnosine (or carcinine and patented compositions thereof) and patented N-acetylcarnosine lubricant eye drops are useful therapeutic tools of a critical telomere length maintenance that may fundamentally be applied in the treatment of age-related sight-threatening eye disorders, prolong life expectancy, increase survival and chronological age of an organism in health control, smoking behavior and disease. "
06/01/2012 - "N-acetylcarnosine 1% lubricant eye drops are considered as an auto-induction prodrug and natural ocular redox state balance therapies with implications in prevention and treatment of serious eye diseases that involve pathways of continuous oxidative damage to ocular tissues(cataracts, primary open-angle glaucoma, age-related macular degeneration) and sight-threatening glycosylation processes (diabetic retinopathy and consequent visual impairment) important for public health. "

Related Drugs and Biologics

1. Lubricant Eye Drops (Artificial Tears)
2. Ophthalmic Solutions (Eye Drops)
3. Carnosine
4. Antioxidants
5. Prodrugs
6. Lubricants
7. Telomerase (Telomerase Reverse Transcriptase)
8. Membrane Lipids
9. Aldehydes
10. carcinine

Related Therapies and Procedures

1. Therapeutics
2. Ophthalmic Administration
3. Nutritional Support (Artificial Feeding)
4. Rejuvenation
5. Contact Lenses